
Print Options
PrintThe Whole
Instrument
PrintThe Whole
Schedule
PrintThis
Section
only
Status:
This is the original version (as it was originally made).
Amendment of the Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
This section has no associated Explanatory Memorandum
7. In regulation 23 (insertion of regulation 57 (functions in relation to good clinical practice)), in the inserted regulation 57—
(a)in paragraph (1), after “Regulations may” insert “, in respect of Great Britain”;
(b)for paragraphs (2) and (3) substitute—
“(2) Any power to make regulations under paragraph (1)—
(a)is exercisable by the Secretary of State by statutory instrument;
(b)includes power to make—
(i)different provision for different purposes or different areas;
(ii)consequential, supplementary, incidental, transitional, transitory or saving provisions, including consequential amendments to these Regulations.
(3) Regulations under paragraph (1) are subject to annulment in pursuance of a resolution of either House of Parliament.”.
Back to top